Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

Dexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...

DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants. The maker ...

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last ...

Cheng Xin / Getty Images DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants. The maker of glucose monitoring devices said ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.

Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...

DexCom might or might not recover soon, but the company's long-term prospects remain attractive. The medical device specialist focuses on diabetes care. It is a leader in the continuous glucose ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...